Functional systemic CD4 immunity is a differential factor for clinical responses to PD-L1/PD-1 blockade therapy in lung cancer
M. Zuazo, H. Arasanz, G. Fernandez-Hinojal, M. J. Garcia-Granda, M. Gato, A. Bocanegra, B. Hernandez, M. Martinez, L. Teijeira, I. Morilla, M. J. Lecumberri, A. Fernandez de Lascoiti, R. Vera, G. Kochan, D. Escors
This study identifies functional systemic CD4 immunity as a key predictor of response to PD-L1/PD-1 blockade therapy in lung cancer patients.
bioRxiv · Jan 9, 2019Cancer Biology